|Bid||0.00 x 66000|
|Ask||839.00 x 112600|
|Day's Range||833.75 - 837.50|
|52 Week Range||467.40 - 853.00|
|Beta (3Y Monthly)||-0.16|
|PE Ratio (TTM)||114.38|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Europe's listed companies are expected to generate 1.2 trillion euros (£1.0 trillion) in revenue from the United States this year, highlighting what's at stake as global trade tensions grow and earnings and economic growth stall. Analysts and investors say that based on revenues, European companies are more vulnerable to a dispute than their competitors in the United States. U.S. President Donald Trump is due to decide by Saturday whether to impose duties on car imports, potentially posing another significant threat to global growth and denting Europe's prized auto sector.
Moody's Investors Service ("Moody's") assigned a Baa2 rating to the new senior unsecured notes offering of Boston Scientific Corporation ("Boston Scientific"). There are no changes to Moody's existing ratings of Boston Scientific including the Baa2 senior unsecured long-term rating and the Prime-2 short-term rating. Boston Scientific's Baa2 senior unsecured ratings reflects its meaningful scale in the medical device industry with revenues of approximately $10 billion.
According to a report by the World Gold Council (or WGC), holdings in gold ETFs rose for the second consecutive month in November to 21.2 tons to a total of 2,365 tons. It also said that the global gold-backed ETF flows are now positive in US dollar (UUP) terms for the year. ETF flows were positive for the first time in four months. The renewed buying interest from investors was on account of increased market volatility and the equity market sell-off.
Moody's Investors Service ("Moody's") today affirmed Boston Scientific Corporation's Baa2 senior unsecured ratings and its Prime-2 commercial paper rating. The affirmation of the ratings follows Boston Scientific's announcement that it has reached an agreement to acquire BTG Plc, a UK-based medical products company. Under the terms of the offer, Boston Scientific will acquire BTG for approximately GBP 3.3 billion ($4.2 billion at current exchange rates).
UK shares fell to three-week lows on Tuesday as investors dumped financial, oil and mining stocks amid renewed fears about Brexit and Rome's budget showdown with Brussels, and Wall Street gloom across tech and retail spread across Europe. The FTSE 100 (.FTSE) ended the day down 0.8 percent, its third straight daily loss, with sentiment also hurt by heavy losses in the euro zone after a report Apple has cut production triggered a global rout in tech stocks. While the political drama of last week has largely calmed, investors worried anew about UK Prime Minister Theresa May's struggle to get her draft Brexit deal passed in Brussels and at home, with banks bearing the brunt of the selling.
Boston Scientific Corp. on Tuesday agreed to buy British healthcare company BTG plc in a $4.2 billion deal. The Marlborough, Mass.-based medical device maker offered $10.77 for each BTG share, representing a premium of 36.
U.S. medical device maker Boston Scientific Corp (BSX.N) has agreed to buy Britain's BTG Plc (BTG.L) for 3.3 billion pounds in cash, adding technology to fight cancer and other serious diseases to its portfolio. Boston Scientific - best known for making stents to prop open clogged heart arteries - has agreed to pay 840 pence per share, representing a premium of 36.6 percent to BTG's previous closing price, the companies said on Tuesday. Shares of BTG soared by a third to 825p by 1200 GMT after touching 832p, their highest level since Jan. 2015.
Boston Scientific Corp. has seen its chance and agreed to buy London-based BTG Plc for 3.3 billion pounds ($4.2 billion). If the deal is consummated, the British maker of medical devices will join the growing list of internationally-flavored U.K. companies falling prey to overseas bidders. This has been a rough year for BTG.
U.S. medical device maker Boston Scientific Corp said it offered to buy British pharmaceutical firm BTG Plc for about 3.3 billion pounds ($4.24 billion) in cash. The offer of 840 pence in cash per share represents a premium of 36.6 percent to BTG's close of 615 pence on Monday. BTG said it plans to recommend the deal to its shareholders as it considers the terms to be fair and reasonable.
European shares recovered on Tuesday as hopes for an easing of the Sino-U.S. trade war and an imminent Brexit deal chased away the previous session's fears of a peak in tech stocks. The pan-European STOXX 600 (.STOXX) rose 0.7 percent in a broad-based recovery with Germany's DAX (.GDAXI) up 1.3 percent as investors turned to some strong results and tech stocks recovered. Europe's tech sector (.SX8P) jumped 1.7 percent, having tumbled sharply in the previous session when Wall Street's tech stocks sank on fears that sales of Apple's iPhone have peaked.
Stocks with market capitalization between $2B and $10B, such as BTG plc (LON:BTG) with a size of UK£2.3b, do not attract as much attention from the investing community as do Read More...
European shares rose in early deals on Tuesday as hopes for a de-escalation of the Sino-U.S. tariff war chased the previous session's fears about a possible downfall of technology stocks after suppliers of Apple cut their forecasts. The pan-European STOXX 600 gained 0.8 percent by 0834 GMT despite Wall Street's main indexes sustaining heavy losses on Monday. Europe's tech sector rose 1.2 percent after falling 3.7 percent during the previous session in New York when the Nasdaq had fallen more than two percent.
As we have followed the gold market over the years, there are three companies that stand out for their persistent ability to create value. Mid-tier producers Agnico Eagle Mines (4.1% of net assets*), B2Gold (6.8% of net assets*), and Randgold, have been able to grow their businesses through accretive acquisitions and exploration success. Randgold and B2Gold have become adept at mitigating geopolitical and social risk with successful operations in Mali, Democratic Republic of Congo (DRC), Ivory Coast, Namibia, Nicaragua, and the Philippines.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...
Pharmaceutical firm BTG (BTG.L) upgraded its sales forecast on Thursday after it included its varicose vein treatment Varithena in its oncology and vascular portfolio and saw strong demand for its tumour-targeting medicines. It had guided to flat to single digit percentage declines in pharmaceutical sales this year when it published its full-year results in May.
How far off is BTG plc (LON:BTG) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairlyRead More...